Arrowstreet Capital’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $359M | Sell |
1,225,800
-121,189
| -9% | -$39.8M | 0.19% | 100 |
|
|
2025
Q4 | $472M | Sell |
1,346,989
-164,615
| -11% | -$55.6M | 0.28% | 84 |
|
|
2025
Q3 | $488M | Buy |
1,511,604
+569,008
| +60% | +$177M | 0.31% | 69 |
|
|
2025
Q2 | $367M | Buy |
942,596
+88,186
| +10% | +$35.5M | 0.26% | 81 |
|
|
2025
Q1 | $372M | Buy |
854,410
+154,529
| +22% | +$62M | 0.3% | 70 |
|
|
2024
Q4 | $258M | Sell |
699,881
-90,559
| -11% | -$37.9M | 0.21% | 95 |
|
|
2024
Q3 | $411M | Sell |
790,440
-143,695
| -15% | -$76.8M | 0.35% | 62 |
|
|
2024
Q2 | $506M | Buy |
934,135
+126,949
| +16% | +$67.1M | 0.45% | 54 |
|
|
2024
Q1 | $419M | Buy |
807,186
+83,990
| +12% | +$41.8M | 0.39% | 58 |
|
|
2023
Q4 | $341M | Sell |
723,196
-199,891
| -22% | -$92.4M | 0.36% | 67 |
|
|
2023
Q3 | $402M | Buy |
923,087
+63,048
| +7% | +$28.6M | 0.49% | 49 |
|
|
2023
Q2 | $382M | Buy |
860,039
+10,160
| +1% | +$4.69M | 0.46% | 51 |
|
|
2023
Q1 | $391M | Sell |
849,879
-47,926
| -5% | -$22.8M | 0.51% | 48 |
|
|
2022
Q4 | $461M | Sell |
897,805
-164,075
| -15% | -$83.3M | 0.64% | 36 |
|
|
2022
Q3 | $482M | Buy |
1,061,880
+138,772
| +15% | +$66.4M | 0.71% | 28 |
|
|
2022
Q2 | $445M | Buy |
923,108
+164,354
| +22% | +$81.3M | 0.63% | 35 |
|
|
2022
Q1 | $373M | Buy |
758,754
+676,769
| +825% | +$309M | 0.47% | 55 |
|
|
2021
Q4 | $38M | Sell |
81,985
-85,146
| -51% | -$35.8M | 0.05% | 333 |
|
|
2021
Q3 | $62.3M | Buy |
167,131
+160,731
| +2,511% | +$61.1M | 0.08% | 267 |
|
|
2021
Q2 | $2.44M | Buy |
+6,400
| New | +$2.45M | ﹤0.01% | 1290 |
|
|
2020
Q4 | – | Sell |
-2,700
| Closed | -$725K | – | 2346 |
|
|
2020
Q3 | $725K | Buy |
+2,700
| New | +$726K | ﹤0.01% | 1907 |
|
|
2020
Q2 | – | Sell |
-51,388
| Closed | -$11.7M | – | 2344 |
|
|
2020
Q1 | $11.7M | Buy |
+51,388
| New | +$14M | 0.03% | 437 |
|
|
2019
Q4 | – | Sell |
-11,811
| Closed | -$2.84M | – | 1793 |
|
|
2019
Q3 | $2.84M | Buy |
11,811
+8,000
| +210% | +$2.19M | 0.01% | 877 |
|
|
2019
Q2 | $1.08M | Sell |
3,811
-58,193
| -94% | -$15.9M | ﹤0.01% | 1041 |
|
|
2019
Q1 | $17.8M | Buy |
62,004
+58,404
| +1,622% | +$16.9M | 0.04% | 397 |
|
|
2018
Q4 | $945K | Buy |
+3,600
| New | +$990K | ﹤0.01% | 969 |
|
|
2018
Q2 | – | Sell |
-855,577
| Closed | -$188M | – | 1135 |
|
|
2018
Q1 | $188M | Sell |
855,577
-904,179
| -51% | -$212M | 0.43% | 58 |
|
|
2017
Q4 | $396M | Sell |
1,759,756
-53,648
| -3% | -$11.4M | 0.95% | 20 |
|
|
2017
Q3 | $344M | Buy |
1,813,404
+749,561
| +70% | +$143M | 0.92% | 23 |
|
|
2017
Q2 | $200M | Buy |
1,063,843
+255,690
| +32% | +$45.9M | 0.61% | 41 |
|
|
2017
Q1 | $134M | Buy |
+808,153
| New | +$129M | 0.49% | 47 |
|
|
2016
Q4 | – | Sell |
-642,238
| Closed | -$80.5M | – | 1876 |
|
|
2016
Q3 | $80.5M | Buy |
642,238
+83,100
| +15% | +$10.7M | 0.26% | 87 |
|
|
2016
Q2 | $73.4M | Buy |
559,138
+426,970
| +323% | +$58.4M | 0.24% | 107 |
|
|
2016
Q1 | $18.4M | Buy |
132,168
+83,747
| +173% | +$11.2M | 0.08% | 260 |
|
|
2015
Q4 | $6.75M | Sell |
48,421
-363,353
| -88% | -$50.1M | 0.03% | 461 |
|
|
2015
Q3 | $57.6M | Sell |
411,774
-178,436
| -30% | -$26.8M | 0.27% | 83 |
|
|
2015
Q2 | $96.9M | Buy |
590,210
+17,526
| +3% | +$2.8M | 0.55% | 45 |
|
|
2015
Q1 | $88.4M | Sell |
572,684
-333,791
| -37% | -$47.5M | 0.54% | 45 |
|
|
2014
Q4 | $114M | Buy |
906,475
+352,649
| +64% | +$43.6M | 0.65% | 32 |
|
|
2014
Q3 | $66.2M | Buy |
553,826
+471,207
| +570% | +$54M | 0.36% | 73 |
|
|
2014
Q2 | $8.89M | Sell |
82,619
-143,209
| -63% | -$14.8M | 0.05% | 320 |
|
|
2014
Q1 | $22.5M | Buy |
225,828
+98,470
| +77% | +$8.91M | 0.14% | 164 |
|
|
2013
Q4 | $11.8M | Buy |
127,358
+82,829
| +186% | +$7.36M | 0.06% | 264 |
|
|
2013
Q3 | $3.72M | Buy |
+44,529
| New | +$3.82M | 0.02% | 432 |
|
Other funds holding ELV
VCM
VPM
Arrowstreet Capital's ELV Position: Q1 2026 in Review
Arrowstreet Capital reduced its Elevance Health (ELV) stake by 9% in Q1 2026, selling an estimated $39.8M and leaving 1,225,800 shares worth $359M. The position accounts for 0.19% of the portfolio, ranked #100.
Arrowstreet Capital first reported a position in ELV in Q3 2013 and has held it in 44 quarters since. The position peaked at $506M in Q2 2024. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Arrowstreet Capital held 1,225,800 shares of Elevance Health worth $359M as of Q1 2026.
- Arrowstreet Capital sold 121,189 Elevance Health shares in Q1 2026, an estimated $39.8M.
- Elevance Health made up 0.19% of Arrowstreet Capital's portfolio in Q1 2026, its #100 holding.
- Arrowstreet Capital first reported a position in Elevance Health in Q3 2013 and has held it in 44 quarters since.
- Arrowstreet Capital's Elevance Health position peaked at $506M in Q2 2024.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.